Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Oricell Therapeutics Raises $110M+ in Pre‑IPO Round – Accelerates Global Expansion of First‑in‑Class CAR‑T for Liver Cancer

Fineline Cube Apr 12, 2026
Company Deals

Gilead Exercises Option on Kymera’s KT-200 for $45M – Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies

Fineline Cube Apr 12, 2026
Company Deals

Sinocelltech to Raise RMB 900M via Private Placement – Funds Working Capital for Biologics Pipeline

Fineline Cube Apr 12, 2026
Company Deals

NorrDia Medical Raises RMB 100M+ to Complete Bellco Acquisition – Builds Global Blood Purification Platform

Fineline Cube Apr 12, 2026
Company Deals

Vivatides Therapeutics Closes $54M Series A to Advance Extrahepatic Oligonucleotide Delivery Platform – Led by Qiming Venture Partners

Fineline Cube Apr 12, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Duality Biologics Files NMPA Market Approval for DB-1303 HER2 ADC – Phase III Study Beats T-DM1 in Metastatic Breast Cancer

Fineline Cube Apr 12, 2026
Company Drug

Sino Biopharm Doses First Patient in Phase II Study of Kylo-11 – First-in-Class siRNA Targeting LPA for Cardiovascular Disease

Fineline Cube Apr 12, 2026
Company Deals

CStone Pharmaceuticals Partners with SteinCares for Sugemalimab Commercialization in Latin America

Fineline Cube Jan 27, 2025

CStone Pharmaceuticals (HKG: 2616), a China – based biopharmaceutical company focused on oncology drug development,...

Company Medical Device

MicroPort’s Fireliums Receives NMPA Approval for Coronary Bifurcation Stenosis Treatment

Fineline Cube Jan 27, 2025

Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced receiving marketing approval from...

Company Medical Device

MicroPort’s TomaHawk Intravascular Shock Wave Therapy Device Approved by NMPA

Fineline Cube Jan 27, 2025

Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced receiving marketing approval from...

Company Drug

FDA Clears sBLA for Eisai and Biogen’s Leqembi Maintenance Dosing

Fineline Cube Jan 27, 2025

Partners Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have announced that the...

Company Deals Medical Device

Jiangsu Yuyue Partners with Inogen for International Distribution and R&D

Fineline Cube Jan 27, 2025

China-based Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (SHE: 002223) has struck a partnership...

Company Drug

Guangzhou Innogen’s Efsubaglutide Alfa Approved by NMPA for Type 2 Diabetes

Fineline Cube Jan 27, 2025

China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd, a biopharma focused on metabolic diseases, has announced...

Company Drug

MSD and Eisai’s Keytruda/Lenvima Combo Shows Promise in Gastroesophageal Cancer Study

Fineline Cube Jan 26, 2025

Partners Merck, Sharp & Dohme (MSD, NYSE: MRK) and Eisai (TYO: 4523) have announced the...

Policy / Regulatory

NHSA Targets Low-Volume Drugs in National Reimbursement List

Fineline Cube Jan 26, 2025

The National Healthcare Security Administration (NHSA) in China has released a list of 131 drugs...

Company Drug

Novo Nordisk’s Amycretin Shows Promising Weight Loss Results in Phase Ib/IIa Study

Fineline Cube Jan 26, 2025

Denmark – based pharmaceutical giant Novo Nordisk A / S (NYSE: NVO) has announced topline...

Company Deals

Jiangsu Vcare PharmaTech Secures RMB200 Million in Series C+ Financing

Fineline Cube Jan 26, 2025

Jiangsu Vcare PharmaTech Co., Ltd., a China – based high – tech pharmaceutical company, has...

Company Deals

GeneQuantum Secures $13 Billion Deals with Biohaven and AimedBio for ADC Development

Fineline Cube Jan 26, 2025

Suzhou based biotech firm GeneQuantum has announced a series of major commercial cooperation pacts worth...

Company Deals

Sinopharm Partners with Biogen for Comprehensive Service Agreement

Fineline Cube Jan 26, 2025

China-based Sinopharm Group Co., Ltd (HKG: 1099) has entered into a strategic partnership with US-based...

Company Drug

Boehringer Ingelheim’s Nerandomilast Granted Priority Review for IPF in China

Fineline Cube Jan 26, 2025

German pharmaceutical giant Boehringer Ingelheim has announced that the Center for Drug Evaluation (CDE) of...

Company Deals

Mirxes Holding Files for Hong Kong IPO with Focus on miRNA Test Kits

Fineline Cube Jan 26, 2025

Mirxes Holding Company Ltd, a Singapore – headquartered RNA technology company, has received a filing...

Company Drug

Shenzhen Kangtai Halts COVID-19 Vaccine Development Amid Market Shifts

Fineline Cube Jan 26, 2025

Shenzhen based biopharmaceutical company Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the...

Company Medical Device

Huadong Medicine’s Ellansé M Filing Accepted by China’s NMPA

Fineline Cube Jan 26, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that its market filing for the...

Company Digital Drug

China Medical System Partners with MabGeek for Innovative Drug MG-K10

Fineline Cube Jan 26, 2025

China Medical System Holdings (CMS; HKG: 0867) has announced a new license agreement with MabGeek...

Company Drug

BioCity Biopharma Launches Phase III Study for Kidney Disease Drug SC0062

Fineline Cube Jan 25, 2025

BioCity Biopharma, a leading biopharmaceutical company, has announced the initiation of a Phase III clinical...

Company Deals

ConjuStar Raises RMB100 Million to Advance X-Drug Conjugates Pipeline

Fineline Cube Jan 24, 2025

ConjuStar, a specialist in X-Drug conjugates (XDCs) based in Tianjin, has reportedly raised RMB100 million...

Company Drug

Hengrui’s Long-Acting Insulin Analogue Accepted for Review by China’s NMPA

Fineline Cube Jan 24, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that its market filing for...

Posts pagination

1 … 203 204 205 … 648

Recent updates

  • Duality Biologics Files NMPA Market Approval for DB-1303 HER2 ADC – Phase III Study Beats T-DM1 in Metastatic Breast Cancer
  • Oricell Therapeutics Raises $110M+ in Pre‑IPO Round – Accelerates Global Expansion of First‑in‑Class CAR‑T for Liver Cancer
  • Sino Biopharm Doses First Patient in Phase II Study of Kylo-11 – First-in-Class siRNA Targeting LPA for Cardiovascular Disease
  • Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System – Expands Global Mitral Regurgitation Pipeline
  • Henlius Biotech Secures Two New NMPA Approvals for Hanlikang – Expands Rituximab Biosimilar into DLBCL Combination Therapies
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Duality Biologics Files NMPA Market Approval for DB-1303 HER2 ADC – Phase III Study Beats T-DM1 in Metastatic Breast Cancer

Company Deals

Oricell Therapeutics Raises $110M+ in Pre‑IPO Round – Accelerates Global Expansion of First‑in‑Class CAR‑T for Liver Cancer

Company Drug

Sino Biopharm Doses First Patient in Phase II Study of Kylo-11 – First-in-Class siRNA Targeting LPA for Cardiovascular Disease

Company Medical Device

Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System – Expands Global Mitral Regurgitation Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.